Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial

MLA

de Guibert, Sophie, et al. “Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial.” Blood, vol. 124, no. 21, Dec. 2014, p. 3341. EBSCOhost, https://doi.org/10.1182/blood.V124.21.3341.3341.

APA

de Guibert, S., Dilhuydy, M.-S., Ysebaert, L., Sanhès, L., Choquet, S., Aurran-Schleinitz, T., Guieze, R., Mahe, B., Daguindau, N., Araujo, C., Saad, H., Ferrant, E., Cazin, B., Feugier, P., Dreyfus, B., Alain, D., Lepretre, S., Le Garff-Tavernier, M., Lauren, V., … Tournilhac, O. (2014). Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial. Blood, 124(21), 3341. https://doi.org/10.1182/blood.V124.21.3341.3341

Chicago

de Guibert, Sophie, Marie-Sarah Dilhuydy, Loic Ysebaert, Laurence Sanhès, Sylvain Choquet, Therese Aurran-Schleinitz, Romain Guieze, et al. 2014. “Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial.” Blood 124 (21): 3341. doi:10.1182/blood.V124.21.3341.3341.